|
|
|
|
Ensysce Biosciences Inc (ENSC) |
|
|
|
| |
Ensysce Biosciences Inc 's Working Capital Ratio
ENSC's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth
Regardless of the sequential decrease in Current Liabilities, during the second quarter 2024, Working Capital Ratio deteriorated to 1.88 below Ensysce Biosciences Inc 's average Working Capital Ratio.
Within Major Pharmaceutical Preparations industry 220 other companies have achieved higher Working Capital Ratio than Ensysce Biosciences Inc in second quarter 2024. While Working Capital Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 1211 to 1692.
Explain Working Capital Ratio
How much in Current Assets ENSC´s has?
What is the value of ENSC´s Current Liabilities?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| ENSC Working Capital Ratio |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
(Dec 31 2023)
IV. Quarter |
(Jun 30 2023)
II. Quarter |
(Mar 31 2023)
I. Quarter |
| Y / Y Current Liabilities Change |
-67.14 % |
-82.71 % |
-72.02 % |
-69.48 % |
-54.83 % |
| Y / Y Current Assets Change |
-27.02 % |
-11.37 % |
-70.13 % |
-18.62 % |
-71.09 % |
| Working Capital Ratio MRQ |
1.88 |
2.87 |
0.69 |
2.33 |
0.85 |
| ENSC's Total
Ranking |
# 1692 |
# 1211 |
# 3461 |
# |
# 2308 |
| Seq. Current Liabilities Change |
-20.14 % |
-50.91 % |
32.41 % |
-36.69 % |
-57.99 % |
| Seq. Current Assets Change |
-47.63 % |
105.19 % |
-60.91 % |
73.71 % |
-36.39 % |
| Working Capital Ratio second quarter 2024 Company Ranking |
| Within: |
No. |
| Major Pharmaceutical Preparations Industry |
# 221 |
| Healthcare Sector |
# 459 |
| Overall Market |
# 1690 |
| Working Capital Ratio Statistics |
| High |
Average |
Low |
| 14.77 |
3.63 |
0.56 |
| (Dec 31 2017) |
|
(Dec 31 2022) |
Cumulative Ensysce Biosciences Inc 's Working Capital Ratio
ENSC's Working Capital Ratio for the trailling 12 Months
ENSC Working Capital Ratio |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
(Dec 31 2023)
IV. Quarter |
(Jun 30 2023)
II. Quarter |
(Mar 31 2023)
I. Quarter |
| Y / Y Current Liabilities TTM Growth |
-67.14 % |
-82.71 % |
-72.02 % |
-69.48 % |
-54.83 % |
| Y / Y Current Assets TTM Growth |
-27.02 % |
-11.37 % |
-70.13 % |
-18.62 % |
-71.09 % |
| Working Capital Ratio TTM |
1.74 |
1.41 |
0.87 |
0.8 |
0.7 |
| Total
Ranking TTM |
# 1316
| # 2879
| # 2590
| # 4170
| #
|
| Seq. Current Liabilities TTM Growth |
-20.14 % |
-50.91 % |
32.41 % |
-36.69 % |
-57.99 % |
| Seq. Current Assets TTM Growth |
-47.63 % |
105.19 % |
-60.91 % |
73.71 % |
-36.39 % |
On the trailing twelve months basis Current Liabilities decreased faster than Ensysce Biosciences Inc 's average Current Assets, this led to increase in in Ensysce Biosciences Inc 's Working Capital Ratio to 1.74, above ENSC average Working Capital Ratio. Working Capital Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 205 other companies have achieved higher Working Capital Ratio than Ensysce Biosciences Inc . While Working Capital Ratio overall ranking has improved so far to 1316, from total ranking during the twelve months ending first quarter 2024 at 2879.
Explain Working Capital Ratio
How much in Current Assets ENSC´s has?
What is the value of ENSC´s Current Liabilities?
| TTM Working Capital Ratio Company Ranking |
| Within: |
No. |
| Within the Major Pharmaceutical Preparations Industry |
# 206 |
| Healthcare Sector |
# 436 |
| Within the Market |
# 1316 |
| trailing twelve months Working Capital Ratio Statistics |
| High |
Average |
Low |
| 2.38 |
1.24 |
0.7 |
| (Jun 30 2021) |
|
(Mar 31 2023) |
|
Date modified: 2024-10-01T08:58:56+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
